Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection
Shukaib Arslan, Shahrukh K. Hashmi(Mayo Clinic), Stacey A. Rizza(Mayo Clinic), Willis H. Navarro(University of California, San Francisco), Mark R. Litzow(Dana-Farber Cancer Institute), Nathan W. Cummins(Mayo Clinic), Andrew D. Badley(Mayo Clinic)
Cited by 19
Related Papers
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
|Blood|2017|296
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors
|Haematologica|2021|236
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
|New England Journal of Medicine|2024|213
Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
|Biology of Blood and Marrow Transplantation|2014|210
Diffuse Alveolar Hemorrhage in Hematopoietic Stem Cell Transplant Recipients
|American Journal of Respiratory and Critical Care Medicine|2002|204